Time-limited acalabrutinib plus venetoclax improves outcomes vs chemoimmunotherapy, offering the first FDA-approved all-oral fixed-duration CLL option, explains Adam Kittai, MD. The study compared ...

Suchitra Sundaram, MD, shares that ASH 2025 presented major advances in chronic lymphocytic leukemia (CLL) across both time‑limited and continuous treatment strategies, and emphasized the growing role ...

Around 200 people with chronic lymphocytic leukaemia (CLL) whose disease has returned after treatment are set to benefit from a new treatment option. Our draft guidance recommends pirtobrutinib (also ...

Abbreviations: BR, bendamustine plus rituximab; CLL, chronic lymphocytic leukemia; ECOG PS, Eastern Cooperative Oncology Group performance status; IGHV, immunoglobulin heavy-chain variable region; SLL ...

Phase 1/2 studies of DZD8586 in CLL/SLL patients after covalent or non-covalent BTK inhibitors and BTK degraders. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This abstract ...

At SNHU, we want to make sure you have the information you need to make decisions about your education and your future—no matter where you choose to go to school. That's why our informational articles ...

There are two types of inflammation: acute and chronic. Acute inflammation is the kind that lasts a few hours, days, or weeks, and it’s helpful to healing. It’s your immune system’s response when ...

I'm a woman of many talents. Travel packing is not one of them. Yes, I leave it to the last minute. Yes, I pull my entire wardrobe out onto my bed, and still somehow end up packing a stuffed suitcase ...

Rebecca Torchia is a web editor for EdTech: Focus on K–12. Previously, she has produced podcasts and written for several publications in Maryland, Washington, D.C., and her hometown of Pittsburgh.